Comorbidity in Juvenile Idiopathic Arthritis

Objectives of the Project

The purpose of this proposal is to study the presence of comorbidity and symptoms developing under therapy of patients followed in the 3 largest JIA registries in Europe. We assume that comorbidity in a disease such as JIA significantly increases the burden of the disease and thus has major effects on quality of life.

Read more

Facts and Figures

Project Lead
Prof. N. Wulffraat
Pharmachild, UMC
FOREUM research grant: € 300.000
2017, Duration 3 years

Meet the Team

Prof. N. Wulffraat
Pharmachild, UMC
Prof. J. Swaart
Pharmachild, UMC
Prof. K. Hyrich
UK Registries, University of Manchester
Dr. M. Lunt
UK Registries, University of Manchester
Dr. N. Ruperto
Pharmachild, IRCCS G. Gaslini
Dr. K. Minden
Biker/JUMBO, Charité Berlin, St. Augustin
Dr. J. Klotsche
Biker/JUMBO, Charité Berlin, St. Augustin
Dr. G. Horneff
Biker/JUMBO, Charité Berlin, St. Augustin
Mrs. W. Costello
European Network for Children with Arthritis ENCA
Mr. C. Schoemaker
Dutch JIA parent organisation

Patient Voice

Quality parameters are highly relevant for patient organisations since these must be addressed by local health care providers and authorities.

ENCA (European Network for Children with Arthritis) representatives are part of our steering committee. ENCA has parents trained in research, epidemiology and health care amongst its members.


Patient involvement through ENCA can help us analysing the relevance of these complications for the disease burden. They will be actively involved in ranking the importance of the observed comorbidities/complications and thus in discussing priorities for further research.

Parents/patients can evaluate obtained information on these events for websites with patient information or hospitals.